MEI PharmaMEIP
About: MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Employees: 28
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.07% more ownership
Funds ownership: 41.09% [Q2] → 41.16% (+0.07%) [Q3]
2% less capital invested
Capital invested by funds: $7.96M [Q2] → $7.81M (-$147K) [Q3]
6% less funds holding
Funds holding: 32 [Q2] → 30 (-2) [Q3]
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Research analyst outlook
We haven’t received any recent analyst ratings for MEIP.
